NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
NEW YORK, September 14, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, September 14, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to…
Irvine Labs, Inc. has applied to register as an importer of basic classes of controlled substances, with comments due by 14 October 2026.
The Drug Enforcement Administration published Irvine Labs, Inc.'s application on 14 September 2026. The notice opens a comment period ending on 14 October 2026 and refers to supplementary information for details of th...
Cambrex High Point, Inc. has applied to register as a bulk manufacturer of basic classes of controlled substances.
Cambrex High Point, Inc. submitted an application to be registered as a bulk manufacturer of basic classes of controlled substances. The available information does not specify which substances are covered.
Definium Therapeutics reported a third phase 3 success for LSD-based DT120 ODT in anxiety, supporting an expected FDA filing later this year.
In the 245-patient Panorama trial, a 100 μg dose reduced HAM-A scores by 9.8 points at week 12, compared with 4.7 points for placebo. The trial met key secondary endpoints and found no new safety concerns. Definium pl...
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
NEW YORK, September 13, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to…
Kambo Is More Dangerous Than You Think
This Week’s Sunday Insider: The risks of Kambo are well-documented…the benefits are not.
The Day They Came and Arrested the Literary Imagination: Version 2, with small corrigenda
What I’m not supposed to write as a American (mostly) caucasian fiction writer
Ketamine reveals shifting brain activity patterns linked to depression improvement in older adults
Researchers at Texas A&M University's Naresh K. Vashisht College of Medicine have identified time-specific patterns of brain activity following ketamine treatment in older adults with treatment-resistant depression.
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
ATLANTA, September 11, 2026--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has…
Psilocybin may help prevent chemo-induced nerve pain; Definium scores second FDA Breakthrough Therapy designation
Plus: New Zealand approves two psychiatrists to prescribe MDMA; What to expect from the FDA psychedelics hearing on Monday
It’s Time to Redefine “Sober”
Welcome to The Psychedelic Blog. An independent media platform covering drugs, altered states & the culture surrounding them.
Ayahuasca and Wellness Spaces Aren’t Built for Disabled and Autistic Bodies
Here's what happens when the medicine heals your mind, but the body keeps the score long after. [...] Read More... The post Ayahuasca and Wellness Spaces Aren’t Built for Disabled and Autistic Bodies appeared first on...
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands…